Table of Contents
ISRN Gastroenterology
Volume 2011 (2011), Article ID 194324, 5 pages
http://dx.doi.org/10.5402/2011/194324
Review Article

Immunomodulators and Immunosuppressants for Japanese Patients with Ulcerative Colitis

1Division of Gastroenterology, Shiga University of Medical Science, Shiga 521-2192, Japan
2Division of Clinical Nutrition, Shiga University of Medical Science, Shiga 521-2192, Japan
3Division of Mucosal Immunology, Graduate School of Medicine, Shiga University of Medical Science, Shiga 521-2192, Japan

Received 17 February 2011; Accepted 1 April 2011

Academic Editors: J. M. Pajares and C. C. Schimanski

Copyright © 2011 Shigeki Bamba et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. W. J. Sandborn, “A critical review of cyclosporin therapy in inflammatory bowel disease,” Inflammatory Bowel Disease, vol. 1, no. 3, pp. 48–63, 1995. View at Google Scholar
  2. G. C. Actis, A. Ottobrelli, A. Pera et al., “Continuously infused cyclosporine at low dose is sufficient to avoid emergency colectomy in acute attacks of ulcerative colitis without the need for high-dose steroids,” Journal of Clinical Gastroenterology, vol. 17, no. 1, pp. 10–13, 1993. View at Google Scholar · View at Scopus
  3. S. Lichtiger, D. H. Present, A. Kornbluth et al., “Cyclosporine in severe ulcerative colitis refractory to steroid therapy,” The New England Journal of Medicine, vol. 330, no. 26, pp. 1841–1845, 1994. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  4. R. D. Cohen, A. L. Brodsky, and S. B. Hanauer, “A comparison of the quality of life in patients with severe ulcerative colitis after total colectomy versus medical treatment with intravenous cyclosporin,” Inflammatory Bowel Diseases, vol. 5, no. 1, pp. 1–10, 1999. View at Google Scholar · View at Scopus
  5. M. Seo, M. Okada, T. Yao, M. Ueki, S. Arima, and M. Okumura, “An index of disease activity in patients with ulcerative colitis,” The American Journal of Gastroenterology, vol. 87, no. 8, pp. 971–976, 1992. View at Google Scholar · View at Scopus
  6. S. Bamba, T. Tsujikawa, O. Inatomi et al., “Factors affecting the efficacy of cyclosporin A therapy for refractory ulcerative colitis,” Journal of Gastroenterology and Hepatology, vol. 25, no. 3, pp. 494–498, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  7. H. Ban, A. Andoh, H. Imaeda et al., “The multidrug-resistance protein 4 polymorphism is a new factor accounting for thiopurine sensitivity in Japanese patients with inflammatory bowel disease,” Journal of Gastroenterology, vol. 45, no. 10, pp. 1014–1021, 2010. View at Publisher · View at Google Scholar · View at PubMed
  8. K. Fellermann, Z. Tanko, K. R. Herrlinger et al., “Response of refractory colitis to intravenous or oral tacrolimus (FK506),” Inflammatory Bowel Diseases, vol. 8, no. 5, pp. 317–324, 2002. View at Google Scholar
  9. H. Ogata, T. Matsui, M. Nakamura et al., “A randomised dose finding study of oral tacrolimus (FK506) therapy in refractory ulcerative colitis,” Gut, vol. 55, no. 9, pp. 1255–1262, 2006. View at Publisher · View at Google Scholar · View at PubMed
  10. O. H. Nielsen, B. Vainer, and J. Rask-Madsen, “Review article: the treatment of inflammatory bowel disease with 6-mercaptopurine or azathioprine,” Alimentary Pharmacology and Therapeutics, vol. 15, no. 11, pp. 1699–1708, 2001. View at Publisher · View at Google Scholar
  11. D. J. Adler and B. I. Korelitz, “The therapeutic efficacy of 6-mercaptopurine in refractory ulcerative colitis,” The American Journal of Gastroenterology, vol. 85, no. 6, pp. 717–722, 1990. View at Google Scholar
  12. W. Sandborn, L. Sutherland, D. Pearson, G. May, R. Modigliani, and C. Prantera, “Azathioprine or 6-mercaptopurine for inducing remission of Crohn's disease,” Cochrane Database of Systematic Reviews, Article ID CD000545, 2000. View at Google Scholar
  13. T. Hibi and H. Ogata, “Novel pathophysiological concepts of inflammatory bowel disease,” Journal of Gastroenterology, vol. 41, no. 1, pp. 10–16, 2006. View at Publisher · View at Google Scholar · View at PubMed
  14. R. B. Gearry, M. L. Barclay, M. J. Burt, J. A. Collett, and B. A. Chapman, “Thiopurine drug adverse effects in a population of New Zealand patients with inflammatory bowel disease,” Pharmacoepidemiology and Drug Safety, vol. 13, no. 8, pp. 563–567, 2004. View at Publisher · View at Google Scholar · View at PubMed
  15. J. M. Van Dieren, B. E. Hansen, E. J. Kuipers, E. E. Nieuwenhuis, and C. J. Van Der Woude, “Meta-analysis: inosine triphosphate pyrophosphatase polymorphisms and thiopurine toxicity in the treatment of inflammatory bowel disease,” Alimentary Pharmacology and Therapeutics, vol. 26, no. 5, pp. 643–652, 2007. View at Publisher · View at Google Scholar · View at PubMed
  16. J. P. Gisbert and F. Gomollón, “Thiopurine-induced myelotoxicity in patients with inflammatory bowel disease: a review,” The American Journal of Gastroenterology, vol. 103, no. 7, pp. 1783–1800, 2008. View at Publisher · View at Google Scholar · View at PubMed
  17. N. Takatsu, T. Matsui, Y. Murakami et al., “Adverse reactions to azathioprine cannot be predicted by thiopurine S-methyltransferase genotype in Japanese patients with inflammatory bowel disease,” Journal of Gastroenterology and Hepatology, vol. 24, no. 7, pp. 1258–1264, 2009. View at Publisher · View at Google Scholar · View at PubMed
  18. C. W. Lees, A. K. Maan, B. Hansoti, J. Satsangi, and I. D. R. Arnott, “Tolerability and safety of mercaptopurine in azathioprine-intolerant patients with inflammatory bowel disease,” Alimentary Pharmacology and Therapeutics, vol. 27, no. 3, pp. 220–227, 2008. View at Publisher · View at Google Scholar · View at PubMed
  19. J. W. Winter, D. Gaffney, D. Shapiro et al., “Assessment of thiopurine methyltransferase enzyme activity is superior to genotype in predicting myelosuppression following azathioprine therapy in patients with inflammatory bowel disease,” Alimentary Pharmacology and Therapeutics, vol. 25, no. 9, pp. 1069–1077, 2007. View at Publisher · View at Google Scholar · View at PubMed
  20. G. R. Lichtenstein, M. T. Sbreu, R. Cohen, and W. Tremaine, “American gastroenterological association Institute technical review on corticosteroids, immunomodulators, and infliximab in inflammatory bowel disease,” Revista de Gastroenterología de México, vol. 71, no. 3, pp. 351–401, 2006. View at Google Scholar
  21. T. Hibi, M. Naganuma, T. Kitahora, F. Kinjyo, and T. Shimoyama, “Low-dose azathioprine is effective and safe for maintenance of remission in patients with ulcerative colitis,” Journal of Gastroenterology, vol. 38, no. 8, pp. 740–746, 2003. View at Publisher · View at Google Scholar · View at PubMed
  22. L. J. Derijks, L. P. Gilissen, L. G. Engels et al., “Pharmacokinetics of 6-thioguanine in patients with inflammatory bowel disease,” Therapeutic Drug Monitoring, vol. 28, no. 1, pp. 45–50, 2006. View at Publisher · View at Google Scholar
  23. M. Hiratsuka, T. Inoue, F. Omori, Y. Agatsuma, and M. Mizugaki, “Genetic analysis of thiopurine methyltransferase polymorphism in a Japanese population,” Mutation Research—Fundamental and Molecular Mechanisms of Mutagenesis, vol. 448, no. 1, pp. 91–95, 2000. View at Publisher · View at Google Scholar